Gain Therapeutics, Inc.
GANX · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.13 | -0.21 | 0.22 | 0.04 |
| FCF Yield | 7.00% | -6.97% | -5.90% | -12.87% |
| EV / EBITDA | -9.46 | -10.65 | -14.77 | -8.10 |
| Quality | ||||
| ROIC | -106.25% | -65.16% | -45.34% | -44.40% |
| Gross Margin | 0.00% | 0.00% | -25.91% | 0.00% |
| Cash Conversion Ratio | 0.93 | 0.88 | 0.84 | 0.92 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 200.00% | -10.59% | 43.13% | -5.16% |
| Safety | ||||
| Net Debt / EBITDA | 1.27 | 1.95 | 2.94 | 2.54 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -10,935.65 | -9,372.07 | -3,158.97 | -4,567.79 |